Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection

References

• Graybill LA, Kasaro M, Freeborn K, et al. Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis. AIDS. 2020;34(5):761–776.
   PubMed Web of Science ®Google Scholar
• Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS. 2011;25(15):1887.
   PubMed Web of Science ®Google Scholar
• Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis. 2018 June 5;218(1):16–25.
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
   PubMed Web of Science ®Google Scholar
• AVAC. PrEPWatch. New York (NY): AVAC; 2020 [cited 2020 Dec 20].
   Google Scholar
• Davies N, Heffron R. Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. Sex Health. 2018 Nov;15(6):501–512.
   PubMed Web of Science ®Google Scholar
• Delaney W, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006 July;50(7):2471–2477.
   PubMed Web of Science ®Google Scholar
• Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. J Biol Chem. 1998 Oct 16;273(42):27250–27258.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Sueoka C, Lynch GR, et al. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother. 1998 Mar;42(3):687–690.
   PubMed Web of Science ®Google Scholar
• Shaw JP, Sueoko CM, Oliyai R, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res. 1997 Dec;14(12):1824–1829.
   PubMed Web of Science ®Google Scholar
• Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998 Mar;42(3):612–617.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences. Truvada package insert. 2018 [cited 2020 Dec 20]. Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/hiv/truvada/truvada_pi.pdf
   Google Scholar
• Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011 Dec;55(12):5914–5922.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Taha T, Kreitchmann R, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):33–41.
   PubMed Web of Science ®Google Scholar
• Pintye J, Huo Y, Kacanek D, et al. Extent of in-utero transfer of tenofovir from mother to fetus: a paired analysis of hair specimens collected at birth from a cohort in the United States. J Infect Dis. 2020 Feb 24;223(4):638–644.
   Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–2090.
   PubMed Web of Science ®Google Scholar
• Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sept;16(8):502–511.
   PubMed Web of Science ®Google Scholar
• Colbers AP, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013 Mar 13;27(5):739–748.
   PubMed Web of Science ®Google Scholar
• Pyra M, Anderson PL, Hendrix CW, et al. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS. 2018 Aug 24;32(13):1891–1898.
   PubMed Web of Science ®Google Scholar
• Stranix-Chibanda L, Anderson PL, Kacanek D, et al. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa. Clinl Infect Dis. 2020 Dec 20. DOI:https://doi.org/10.1093/cid/ciaa1872
   Google Scholar
• Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med. 2016 Sept;13(9):e1002132.
   PubMed Web of Science ®Google Scholar
• Mugwanya KK, Wyatt C, Celum C, et al. Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):374–380.
   PubMed Web of Science ®Google Scholar
• Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PloS One. 2014;9(3):e90111.
   PubMed Web of Science ®Google Scholar
• Mirembe BG, Kelly CW, Mgodi N, et al. Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287–294.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clinl Infect Dis. 2015 Aug 15;61(4):572–580.
   PubMed Web of Science ®Google Scholar
• Glidden DV, Mulligan K, McMahan V, et al. Brief report: recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177–182.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Policy brief: WHO expands recommendation on oral preexposure prophylaxis oF HIV infection (PrEP). In: WHO, editor. Geneva: WHO; 2015.
   Google Scholar
• US Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update clinical practice guideline. Atlanta: CDC; 2017.
   Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–434.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–422.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6):509–518.
   PubMed Web of Science ®Google Scholar
• Bunge K, Balkus J, Noguchi L, et al., editors. Pregnancy incidence and outcomes in women receiving tenofovir-based PrEP in the VOICE trial. International AIDS conference; 2015; Vancouver, Canada.
   Google Scholar
• Callahan R, Nanda K, Kapiga S, et al. Pregnancy and contraceptive use among women participating in the FEM-PrEP trial. J Acquir Immune Defic Syndr. 2015Feb1;68(2):196–203.
   PubMed Web of Science ®Google Scholar
• Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. Jama. 2014July23-30;312(4):362–371.
   PubMed Web of Science ®Google Scholar
• Scheckter R, McKinstry L, Balkus J, et al., editors. Growth and development of infants born to women enrolled in a clinical trial of tenofovir-based pre-exposure prophylaxis for HIV prevention. HIV Research for Prevention; 2016; Chicago (IL).
   Google Scholar
• Baeten JM, Heffron R, Kidoguchi L, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1–serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099.
   PubMed Web of Science ®Google Scholar
• Heffron R, Mugo N, Hong T, et al. Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS. 2018 July;32(12):1707–1713.
   PubMed Web of Science ®Google Scholar
• Dettinger JC, Kinuthia J, Pintye J, et al. Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya. J Int AIDS Soc. 2019 Sept;22(9):e25378.
   PubMed Web of Science ®Google Scholar
• Dettinger JC, Kinuthia J, Pintye J, et al., editors. No association found between prenatal PrEP Use and adverse infant outcomes: results from a large PrEP implementation program in Kenya. HIV Research for Prevention; 2018; Madrid, Spain.
   Google Scholar
• Dettinger JC, Kinuthia J, Pintye J, et al. PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial. BMJ Open. 2019 Mar 7;9(3):e025122.
   PubMed Web of Science ®Google Scholar
• Dettinger JKJ, Gomez L, Pintye J, et al., Prenatal PrEP exposure and longitudinal birth outcomes in Kenya. Conference on Retroviruses and Opportunistic Infections (CROI); 2020; Boston (MA).
   Google Scholar
• World Health Organization (WHO). Consolidated ARV guidelines: first-line ART for pregnant and breastfeeding women and ARV drugs for their infants. Geneva: WHO; 2013.
   Google Scholar
• Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31(2):213–232.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Uthman OA, Mofenson LM, et al. Safety of tenofovir disoproxil fumarate–based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2017;76(1):1.
   PubMed Web of Science ®Google Scholar
• Fowler MG, Qin M, Fiscus SA, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726–1737.
   PubMed Web of Science ®Google Scholar
• Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9(5):e1001217.
   PubMed Web of Science ®Google Scholar
• Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clinl Infect Dis. 2015;61(6):996–1003.
   PubMed Web of Science ®Google Scholar
• Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26(9):1151.
   PubMed Web of Science ®Google Scholar
• Floridia M, Liotta G, Andreotti M, et al. Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi. J Antimicrob Chemother. 2016;71(11):3206–3211.
   PubMed Web of Science ®Google Scholar
• Jao J, Abrams EJ, Phillips T, et al. In utero tenofovir exposure is not associated with fetal long bone growth. Clinl Infect Dis. 2016;62(12):1604–1609.
   PubMed Web of Science ®Google Scholar
• Viganò A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfeeted children born to HIV-infected mothers. Antivir Ther. 2011;16(8):1259.
   PubMed Web of Science ®Google Scholar
• Siberry G, Tierney C, Stranix-Chibanda L, et al., editors. Impact of maternal tenofovir use on HIV-exposed newborn bone mineral. Conference on Retroviruses and Opportunistic Infections; 2016; Boston (MA).
   Google Scholar
• Cottrell ML, Garrett KL, Prince HMA, et al. Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. J Antimicrob Chemother. 2017 June 1;72(6):1731–1740.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014 May;69(5):1362–1369.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449–455.
   PubMed Web of Science ®Google Scholar
• Mayer KH, Molina J-M, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–254.
   PubMed Web of Science ®Google Scholar
• The Lancet HIV. New PrEP formulation approved … but only for some. 2019 Nov;6(11):e723.
   Google Scholar
• Brooks KM, Momper JD, Pinilla M, et al. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV: results from IMPAACT P1026s. AIDS. 2020.
   Google Scholar
• Chinula L, Brummel S, Ziemba L. Safety and efficacy of DTG vs EFV and TDF vs TAF in pregnancy: IMPAACT 2010 trial [Abstract 130] in special issue: abstracts From the 2020 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2020;28(1):42–43.
   Google Scholar
• Eke AC, Brooks KM, Gebreyohannes RD, et al. Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opin Drug Metab Toxicol. 2020;16(4):333–342.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–2132.
   PubMed Web of Science ®Google Scholar
• Nel A, Van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–2143.
   PubMed Web of Science ®Google Scholar
• Makanani B, Balkus JE, Jiao Y, et al. Pregnancy and infant outcomes among women using the dapivirine vaginal ring in early pregnancy. J Acquir Immune Defic Syndr. 2018;79(5):566.
   PubMed Web of Science ®Google Scholar
• Researchers launch DELIVER study to assess safety of PrEP and dapivirine vaginal ring in pregnant women [Internet]. Pittsburgh; 2020 [cited 2020 Feb 10]. Available from: https://mtnstopshiv.org/news/researchers-launch-deliver-study-assess-safety-prep-and-dapivirine-vaginal-ring-pregnant-women
   Google Scholar
• HPTN 084 study demonstrates superiority of CAB LA to oral FTC/TDF for the prevention of HIV [Internet]. Durham (NC): HPTN; 2020 [cited Nov 9]. Available from: https://www.hptn.org/news-and-events/press-releases/hptn-084-study-demonstrates-superiority-of-cab-la-to-oral-ftctdf-for
   Google Scholar
• Patel P, Thiagarajah S, Ford S, et al., editors. Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes. Conference on Retroviruses and Opportunistic Infections; 2020; Boston (MA).
   Google Scholar
• Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–197.
   PubMed Web of Science ®Google Scholar
• The PHASES Working Group. Ending the evidence gap for pregnant women around HIV & co-infections: a call to action. Chapel Hill (NC); 2020 July.
   Google Scholar